Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04516083|
Recruitment Status : Recruiting
First Posted : August 17, 2020
Last Update Posted : August 18, 2020
The objective of the study is the provide proof of high correlation between somatic and germline mismatch repair instability. This correlation is specifically researched in an area where patients have less access to cancer education and genetic testing for various reasons such as lack of insurance and general accessibility.
The study concentrates on early diagnosis of Lynch syndrome. Lynch syndrome is usually diagnosed from a blood test resulting in a mutation of one of the mismatch repair genes. Those are MLH1, MSH2, MSH 6, PMS2. A mutation in one of these genes creates a mismatch repair instability,hence higher incidence of cancers in specific organ groups. Amongst these organs are the Uterus, Ovaries, Upper genitourinary system, Pancreas and GI system.
The most common endometrial carcinoma which is found in Lynch syndrome is of endometrioid histology. Most patients with known germline mismatch repair instability, have the same somatic mutation. Our study is looking into correlating somatic mutation to germline mutation.
By doing so, patients diagnosed with somatic mismatch repair instability will be also diagnosed with lynch syndrome without germline genetic testing.
Screening programs will be utilized earlier and preventive procedures offered.
Due to less access to educational programs, genetic counseling and testing in underserved areas, patients are sometimes lost to follow up. Our study seeks to prove high correlation between somatic and germline mutations and by doing so, patient will be diagnosed with Lynch syndrome straight after endometrial cancer staging. As a result, increased compliance will be expected and patients will be offered the recommended preventative surgeries and screening protocols.
|Condition or disease||Intervention/treatment|
|Cancer Gene Mutation Lynch Syndrome Endometrial Cancer Somatic Mutation||Diagnostic Test: Mismatch repair instability somatic and germline testing|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||100 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Correlation Between Somatic Mismatch Repair Instability and Germline Mismatch Repair Instability, in Low Socioeconomic Background Population Diagnosed With Endometrial Endometrioid Adenocarcinoma|
|Actual Study Start Date :||December 21, 2019|
|Estimated Primary Completion Date :||December 30, 2020|
|Estimated Study Completion Date :||June 30, 2021|
- Diagnostic Test: Mismatch repair instability somatic and germline testing
Each Endometrial Endometrioid adenocarcinoma is routinely stained for MMR mutation to seek for tumor genetic instability. If stains positive, the patient is called in for genetic blood testing to look for the same mutation in the germline.
- Number of patients who have a somatic mutation at the same time as a germline mutation [ Time Frame: Through study completion, an average of 18 months ]
- Resected tissue during endometrial staging will be immunohistochemically stained for MMR mutation.
- Patient blood test will be checked for MMR gene mutation
- Linear regression curve will be constructed to evaluate the correlation between somatic and germline mutation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04516083
|Contact: Ariel Polonsky, MDemail@example.com|
|Contact: Noah Goldman, MDfirstname.lastname@example.org|
|United States, New Jersey|
|Jersey city medical center||Recruiting|
|Jersey City, New Jersey, United States, 07302|
|Contact: Ariel Polonsky, MD 551-227-6993 email@example.com|